Possis XMI catheter
This article was originally published in The Gray Sheet
Executive Summary
FDA market go-ahead is received for the 4 Fr catheter for removing blood clots from native coronary arteries and coronary bypass grafts. Used with the Minneapolis firm's AngioJet Rheolytic thrombectomy system, the XMI represents the first coronary technological upgrade since March 1999 and includes a lower profile and reduced bleeding risk at the access site, the firm says. The catheter was released for peripheral use in April...